273 related articles for article (PubMed ID: 12457444)
1. Review of the proliferation inhibitor everolimus.
Nashan B
Expert Opin Investig Drugs; 2002 Dec; 11(12):1845-57. PubMed ID: 12457444
[TBL] [Abstract][Full Text] [Related]
2. Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction.
Kovarik JM
Drugs Today (Barc); 2004 Feb; 40(2):101-9. PubMed ID: 15045032
[TBL] [Abstract][Full Text] [Related]
3. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
Valantine H; Zuckermann A
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
[TBL] [Abstract][Full Text] [Related]
4. Optimizing the immunosuppressive regimen in heart transplantation.
Eisen H; Ross H
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
[TBL] [Abstract][Full Text] [Related]
5. Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical developments.
Neumayer HH
Transplantation; 2005 May; 79(9 Suppl):S72-5. PubMed ID: 15880019
[TBL] [Abstract][Full Text] [Related]
6. Everolimus: an immunosuppressive agent in transplantation.
Patel JK; Kobashigawa JA
Expert Opin Pharmacother; 2006 Jul; 7(10):1347-55. PubMed ID: 16805720
[TBL] [Abstract][Full Text] [Related]
7. Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors.
Pascual J
Transplantation; 2005 May; 79(9 Suppl):S76-9. PubMed ID: 15880020
[TBL] [Abstract][Full Text] [Related]
8. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients.
Vítko S; Margreiter R; Weimar W; Dantal J; Viljoen HG; Li Y; Jappe A; Cretin N;
Transplantation; 2004 Nov; 78(10):1532-40. PubMed ID: 15599319
[TBL] [Abstract][Full Text] [Related]
9. Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure.
Kovarik JM; Eisen H; Dorent R; Mancini D; Vigano M; Rouilly M; Hsu CH; Rordorf C
J Heart Lung Transplant; 2003 Oct; 22(10):1117-25. PubMed ID: 14550821
[TBL] [Abstract][Full Text] [Related]
10. Everolimus: a review of its use in renal and cardiac transplantation.
Dunn C; Croom KF
Drugs; 2006; 66(4):547-70. PubMed ID: 16597167
[TBL] [Abstract][Full Text] [Related]
11. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
[TBL] [Abstract][Full Text] [Related]
12. The role of therapeutic monitoring of everolimus in solid organ transplantation.
Mabasa VH; Ensom MH
Ther Drug Monit; 2005 Oct; 27(5):666-76. PubMed ID: 16175142
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study.
Potena L; Prestinenzi P; Bianchi IG; Masetti M; Romani P; Magnani G; Fallani F; Coccolo F; Russo A; Ponticelli C; Rapezzi C; Grigioni F; Branzi A
J Heart Lung Transplant; 2012 Jun; 31(6):565-70. PubMed ID: 22341702
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.
Ettenger RB; Grimm EM
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S22-8. PubMed ID: 11583941
[TBL] [Abstract][Full Text] [Related]
15. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine.
Shihab FS; Cibrik D; Chan L; Kim YS; Carmellini M; Walker R; Zibari G; Pattison J; Cornu-Artis C; Wang Z; Tedesco-Silva H
Clin Transplant; 2013; 27(2):217-26. PubMed ID: 23230975
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
Lehmkuhl H; Hetzer R
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S201-5; discussion S210-1. PubMed ID: 15774323
[TBL] [Abstract][Full Text] [Related]
17. Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure.
Lehmkuhl H; Ross H; Eisen H; Valantine H
Transplant Proc; 2005 Dec; 37(10):4145-9. PubMed ID: 16387066
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with everolimus (Certican) in young renal transplant recipients.
Eris J
Transplantation; 2005 May; 79(9 Suppl):S89-92. PubMed ID: 15880023
[TBL] [Abstract][Full Text] [Related]
19. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
Eisen HJ; Tuzcu EM; Dorent R; Kobashigawa J; Mancini D; Valantine-von Kaeppler HA; Starling RC; Sørensen K; Hummel M; Lind JM; Abeywickrama KH; Bernhardt P;
N Engl J Med; 2003 Aug; 349(9):847-58. PubMed ID: 12944570
[TBL] [Abstract][Full Text] [Related]
20. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]